9/18/2025

Roche acquires 89bio for up to $3.5B, betting on pegozafermin for MASH. Read the latest analysis on both stocks here.

Source: SeekingAlpha

9/15/2025

Explore how President Trump's drug pricing policy impacts pharma stocks like PFE & LLY. Learn investment strategies as regulatory risks rise. Click for more.

Source: SeekingAlpha

9/15/2025

In July, we (my wife and I) received a dividend income total of $4,161.64. My other two Vanguard ETFs – S&P 500 (VOO) and Dividend Appreciation ETF (VIG) - both paid in July.

Source: SeekingAlpha

9/12/2025

Dow Jones hits record 46,000 amid tech and AI gains. What does this mean for investors for the rest of this year? Read the full analysis here.

Source: SeekingAlpha

9/11/2025

GSK plc (NYSE:GSK) is one of the best growth stocks under $50 to buy now. In a report released on September 4, David Evans from Kepler Capital maintained a Hold rating on GSK plc (NYSE:GSK), setting a price target of p1,500.00. GSK plc (NYSE:GSK) released its fiscal Q2 2025 earnings on July 30, reporting total […]

Source: Yahoo

9/11/2025

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Source: Yahoo

9/10/2025

The global chronic myelomonocytic leukemia (CMML) market is set for significant growth due to rising CMML cases, advanced targeted therapies, and increased disease awareness. Recognized as a rare leukemia, CMML's prevalence, especially in aging populations, propels demand for effective treatments. Market growth is fueled by breakthroughs in targeted therapies, immunotherapies, and innovative solutions like CAR-T cell therapies. Enhanced healthcare infrastructure, patient awareness, and reimburse

Source: Yahoo

9/6/2025

GSK plc (NYSE:GSK) is one of the best UK stocks to buy right now. On September 2, TD Cowen analyst Steve Scala maintained a Hold rating on GSK plc (NYSE:GSK) and set a price target of $45.00. The analyst based the rating on the company’s market positioning and strategic outlook, stating that GSK plc’s (NYSE:GSK) […]

Source: Yahoo

9/5/2025

The global acetaminophen market is set to grow at a CAGR of 4.5% from 2025-2033, driven by continued demand for OTC pain relief and expanding access to essential medicines. Widely used across age groups for pain and fever, its usage in combination therapies and among vulnerable populations boosts growth.Dublin, Sept. 05, 2025 (GLOBE NEWSWIRE) -- The "Acetaminophen Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts,

Source: Yahoo

9/3/2025

Health care stocks retreated late Wednesday afternoon, with the NYSE Health Care Index down 0.3% and

Source: Yahoo

9/3/2025

Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index down 0.4% and the H

Source: Yahoo

9/3/2025

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Source: Yahoo

9/3/2025

Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.

Source: Yahoo

9/3/2025

Wave Life Sciences (WVE) said Wednesday that its experimental RNA-editing therapy WVE-006 achieved "

Source: Yahoo

9/2/2025

NVIDIA rides AI and GPU demand, Chevron leverages Hess and Permian output, while Booking gains from strong travel momentum.

Source: Yahoo

9/2/2025

GSK stock adds nearly $5B in value in a month as Specialty Medicines growth, pipeline wins and a strong outlook outweigh vaccine headwinds.

Source: Yahoo

9/2/2025

The nicotine gum market is driven by smoking cessation initiatives and rising health awareness, leading to increased demand for OTC nicotine therapies. Technological advancements enhance product efficacy, and North America leads the market due to health-conscious consumers. Challenges include overcoming social stigmas. Nicotine Gum Market Nicotine Gum Market Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The "Nicotine Gum Market Report by Type, and Region 2025-2033" has been added to ResearchAndMark

Source: Yahoo

8/29/2025

Certainly! Here is the revised version of the article text with em dashes replaced and improved formatting: If you have been eyeing GSK stock and wondering whether now is the time to act, you are definitely not alone. Investors have had plenty to digest in recent months, and the stock’s moves might leave you with more questions than answers. Just in the last 30 days, GSK has managed to climb 4.5%. However, looking back one year, the stock is still down 7.5%. This kind of mixed performance...

Source: Yahoo

8/26/2025

Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.

Source: Yahoo

8/25/2025

European equities traded in the US as American depositary receipts opened the week marginally lower

Source: Yahoo